Study Design: Literature review Objectives: To describe new treatments for painful osteoporotic compression fractures in light of available scientific literature and clinical experience.
In this issue of Spine there are several papers dealing with the topic of vertebroplasty and kyphoplasty. Several of the papers deal with basic biomechanical research, while Liebschner et al present their early clinical results. In this review, we attempt to highlight the important issues around the early results of this relatively new technique of treating painful nonpathologistic vertebral compression fractures.
A painful osteoporotic vertebral fracture can be a significant burden for patients (and their families), impairing physical function and quality of life. 9, 18 Independent of pain, there is morbidity associated with the spinal deformity. 4, 9 In the thoracic spine this is due to decreased lung capacity (FVC and FEV1). 14, 20 In the lumbar spine compression fractures also affect lung capacity, 20 probably due to restrictive airway disease caused by loss of height, and lead to a reduction in abdominal space associated with loss of appetite 19 and secondary sequelae related to poor nutrition. Additionally, vertebral body compression fractures (VCFs) cause chronic pain, sleep loss, decreased mobility, depression, and a loss of independence. 3, 10, 16, 19, 21 The medications taken for symptomatic relief can lead to further mood or mental alterations that compound the medical condition. A large prospective study noted a 23% increase in mortality in women older than 65 years with VCFs compared with age-matched controls. The mortality rate increases with the number of vertebrae fractured. 12 Most painful VCFs are treated palliatively, with bed rest, narcotic analgesics, orthotics, and time. However, bed rest accelerates bone loss 2, 23 and leads to muscle deconditioning, 2 resulting in increased pain from both of these mechanisms. The other treatments for osteoporosis (e.g., hormone replacement, bisphosphonates, calcitonin) are important for the longterm treatment of this disease but often do not provide short-term pain relief.
There are, however, new minimally invasive techniques that have been developed to help stabilize the fractured vertebra and, more importantly, decrease the pain and improve the function of individuals debilitated by painful osteoporotic VCFs. Vertebroplasty provides stabilization and pain relief without deformity improvement. Kyphoplasty helps realign the fractured vertebra (Figures 1-8) , thereby decreasing the kyphosis and creating a void that theoretically allows safer introduction of polymethylmethacrylate (PMMA) into the fractured vertebra.
Methods
Vertebroplasty is the percutaneous injection of PMMA into a fractured vertebral body through one or two bone biopsy needles. It was developed to stabilize the spine, increase mobility, and decrease the pain from symptomatic VCFs caused by me- tastases, angiomas, and osteoporosis. 8, 13 However, vertebroplasty does not address the spinal deformity with its associated morbidity. Also, because PMMA is forced into the cancellous bone matrix, high pressures and runny cement are required, with potential for leaks.
Kyphoplasty involves inserting a bone tamp/balloon ( Figure  2 ) into the vertebral body under image guidance. When inflated with radiocontrast medium (for visualization), the inflatable bone tamp compacts the cancellous bone and reexpands the body. When positioned properly, this technique elevates the endplates without expanding the fractured vertebral body laterally or posteriorly. Two balloons are generally used to provide en masse reduction. Rupture of the balloon (which rarely occurs) is not a hazard, other than exposure to small volumes of radiocontrast medium. Because of the balloons, kyphoplasty allows some correction of the kyphotic deformity by reexpanding the fractured vertebra. The cavity created by the balloons facilitates the controlled placement of thick PMMA under low pressure. This should decrease associated risks related to the deformity, increase filling control, and stabilize the vertebra, thereby safely decreasing pain and improving mobility.
Both techniques start with the percutaneous insertion of a needle (usually 11 G) or guide pin into the fractured vertebra and end with the injection of PMMA. This can be through a transpedicular approach in nearly every case. In the thoracic spine the needle can be inserted extrapedicularly, between the rib head and lateral aspect of the pedicle. In the midlumbar spine a posterolateral approach can be used. Unless a lumbar posterolateral approach is used, a bilateral injection should be performed (although in the laboratory unilateral injections have been shown to provide stable internal fixation 22 ). Fluoroscopy (C-Arm) is used to localize the insertion site and position of the cannula. Local, regional, or general anesthetic can be used.
For vertebroplasty, after correct positioning of the needle, the inner stylet is removed. Contrast material is then injected to assure that the needle is not positioned in the venous flow path. If this occurs, the needle should be repositioned. Injection of PMMA into the venous flow path could result in PMMA embolism or leakage into the spinal canal. Cement, in a thin liquid form, is injected using multiple small syringes (for maximum hand pressure) into the vertebra. The flow of the cement should be followed on the image intensifier. Approximately 1-4 mL per side can usually be accepted.
For kyphoplasty, after proper needle positioning, a series of tools are used to create a working channel. Once inserted, the balloons are then inflated using visual (radiographic), volume, and pressure controls (digital manometer) to create a cavity within the vertebra and to reduce the fracture deformity. Once this has been achieved, the balloons are deflated and removed. Thick cement can be fed through the cannula under low pressure to fill the void created by the balloon tamp. A total of 2-6 mL per side can usually be inserted.
Results
Prospective studies have shown significant improvement in mobility and function after treatment. 5, 7, 15 The literature on percutaneous vertebroplasty reports success rate in pain relief of approximately 70 -90%. 1, [5] [6] [7] 11, 24 Most of the studies have only a small number of patients and limited follow-up. Also, none was randomized or controlled comparing this treatment with standard medical therapy.
Kyphoplasty has only been used actively in the last few years since the FDA approved the inflatable bone tamps in 1998. In an ongoing multicenter study from October 1998 through May 2000, 603 fractures have been reduced and treated by the kyphoplasty technique in the United States. This involved 376 procedures on 340 patients. Early results (with the longest follow-up at 18 months) demonstrate a 90% symptomatic and functional improvement rate. The average anterior height was 83 Ϯ 14% of predicted height before treatment and 99 Ϯ 13% of predicted height after treatment (P Ͻ 0.01). The average midline height was 76 Ϯ 14% before treatment and 92 Ϯ 11% after treatment (n ϭ 17, P Ͻ 0.05). In vertebral bodies with 15% or more of the estimated height lost, the average anterior height improved from 68 Ϯ 12% of predicted height before treatment to 84 Ϯ 14% of predicted height after treatment (P Ͻ 0.01). The average midline height was 64 Ϯ 13% before treatment and 90 Ϯ 12% after treatment (P Ͻ 0.01). The average posterior height was 74 Ϯ 12% before treatment and 88 Ϯ 14% after treatment (P Ͻ 0.05). In both techniques the hospital stay has been short (1-3 days), with many performed as outpatient procedures. Most patients have gone from narcotic analgesics to over-the-counter medications.
Complications
Vertebroplasty Reported significant complications are low (less than 10%) and include increased pain, radiculopathies, spinal cord compression, pulmonary embolism, infection, and rib fractures. 5, 6, 11, 17, 22, 24 Cement leakage, where reported, is common (from 30% to 67% 1, 6, 7, 24 ) but does not generally lead to clinical complications. Cement leakage leading to radiculopathy or spinal cord injury is more common after the treatment of pathologic fractures relating to metastasis or myeloma than for osteoporotic fractures. In the largest report on osteoporotic fractures, the rate of radiculopathy was 4% and the rate of cord compression was less than 0.5%. 1 The majority of reported symptoms were transient.
Kyphoplasty To date, there have been four important complications in these procedures caused by the devices (0.7% per fracture and 1.2% per patient). One patient has had transient fever and hypoxia after placement of PMMA in a liquid form. One patient had an epidural hematoma when a heparin bolus was administered 8 hours postoperatively. Surgical evacuation led to full recovery. One patient had partial motor loss to the lower extremities because of the position of the cement-filling device, with some of the cement delivered into the spinal canal. Surgical decompression was performed and significant recovery occurred. One patient developed an anterior cord syndrome when the extrapedicular approach was used in a patient whose vertebra had fractured through the pedicle-body junction. In this case the body was below the pedicle, making needle insertion difficult. To date, the complications have been related to the needle insertion, not the balloon tamps per se.
Discussion
Vertebroplasty and kyphoplasty are techniques that result in pain relief with a low rate of major complications, for the treatment of painful osteoporotic vertebral compression fractures. Additionally, kyphoplasty reduces acute fractures and allows the controlled placement of PMMA, resulting in improvement of deformity in addition to pain. In appropriately selected patients these treatments provide a means for rapid pain relief and rehabilitation while awaiting the later benefits of medical intervention for the osteoporosis. PMMA is currently the stabilizing bone filler of choice. It has been used successfully to fill defects created by tumors of bone with good long-term outcomes and no cement failures or fractures in vertebra as well as other bones. Modifications will most likely occur to the PMMA, providing packaging in appropriate sizes and altered curing capability for this specific treatment. Additionally, newer pharmaceuticals (which should be bioresorbable) and the development of a bioresorbable balloon to obviate the need to remove it (thereby improving safety and diminishing the likelihood of any leakage of the substrate) are important and hopefully will be developed soon. The early results for both techniques are promising. However, rigorous study to determine efficacy and safety is needed in both techniques. Also, importantly, a better understanding of the natural history of the disorder, when to intervene in the treatment process, and whether maintaining or improving alignment will decrease medical complications of the deformity itself need to be studied. These treatments do provide significant functional and pain improvement to otherwise debilitated, often elderly, individuals.
Key Points
• Osteoporotic vertebral compression fractures have a relatively high morbidity and mortality (often unappreciated).
• Kyphoplasty and vertebroplasty lead to 95% improvement in pain and significant functional improvement in individuals not responding to conventional treatments.
• Kyphoplasty improves fractured vertebral body height and decreases kyphosis by 50%, if performed within 3 months of the onset of the pain.
• Kyphoplasty is associated with less cement leakage than vertebroplasty (these tend to be relatively clinically insignificant in both procedures).
• There is a potential for significant complications from both procedures (pulmonary, gastrointestinal, vascular, and spinal cord and cauda equina injuries).
